TALENT trial at #ESMO26

Neoadjuvant T-DXd +/- anastrozole or sequentially with TCx4 shows modest activity in HER2-low Hr+ early BC

pCR TDXd 7%, TDXd +anastroxole 3%, TDXd x 4 -> TC×4 9%
High baseline levels of HER2 prot potentially associated with higher pCR rates

@OncoAlert